FDA approved the drug INVEGA HAFYERA from Johnson & Johnson. The drug is intended to treat schizophrenia in adults. The approval is based on the results of a phase 3, 12-month study involving 702 people from 20 countries. The study showed that 92.5% of patients who received INVEGA HAFYERA had no relapses.
FDA approved the drug INVEGA HAFYERA from Johnson & Johnson. The drug is intended to treat schizophrenia in adults. The approval is based on the results of a phase 3, 12-month study involving 702 people from 20 countries. The study showed that 92.5% of patients who received INVEGA HAFYERA had no relapses. 
johnsonandjohnson.gcs-web.com
English (US) 